Please login to the form below
cancer patients
This page shows the latest cancer patients news and features for those working in and with pharma, biotech and healthcare.
Green light for Amgen’s KRAS inhibitor in the UK
Lumakras – known as Lumykras in the UK – will be available to 600 lung cancer patients in England through an early access scheme. ... Morgan. “These women don’t have time to wait. Gilead must urgently do the right thing for breast cancer patients
Latest news
-
Results for the inaugural QiC Dermatology Awards 2021 in association with Dermatology in practice announced!
Winner – Supporting Patients with Suspected Skin Cancer During the Pandemic by Luton and Dunstable University Hospital, Bedfordshire Hospitals NHSFT. ... Commended – Harrogate Skin Cancer Support Pack by Harrogate &District NHS Foundation Trust –
-
Roche bets on T-cell therapies with Adaptimmune deal
We believe allogeneic cell therapies could be a game-changing approach for developing personalised therapy platforms based on individual cancer patients’ unique needs,” said James Sabry, global head of partnering at ... their cancer; a significant
-
Lilly and Kumquat Biosciences link up in $2bn-plus immuno-oncology deal
Little is known about Kumquat’s platform, although the company says its mission is ‘to develop innovative therapies to bring about sustainable and life-changing benefits to cancer patients’. ... We look forward to working with Lilly to identify the
-
Merck, Eisai’s Keytruda/Lenvima regimen scores full approval in endometrial cancer
and reinforces the impact of our joint research with Eisai in exploring the potential of this combination to treat more patients with challenging types of cancer,” he added. ... The Keytruda plus Lenvima was previously approved under the FDA’s
-
NHS earmarks £340m for new medicines fund to fast-track ‘innovative’ treatments
The proposed fund is an extension of the Cancer Drugs Fund (CDF), which was designed to enable patients access to promising cancer treatments while further data is collected to support the ... ABPI). "The fund can build on the success of the Cancer Drugs
Results for the inaugural QiC Dermatology Awards 2021 in association with Dermatology in practice announced!
Roche bets on T-cell therapies with Adaptimmune deal
Lilly and Kumquat Biosciences link up in $2bn-plus immuno-oncology deal
Merck, Eisai’s Keytruda/Lenvima regimen scores full approval in endometrial cancer
NHS earmarks £340m for new medicines fund to fast-track ‘innovative’ treatments
More from news
Approximately 0 fully matching, plus 1,132 partially matching documents found.
Latest Intelligence
-
The lessons learned from COVID-19’s impact on oncology trials
Recruiting patients for oncology studies was extremely difficult even before the pandemic as less than 5% of people diagnosed with cancer participate in clinical trials. ... Less screening for cancer has further limited the number of patients recruited
-
The impact of cancer on mental health during COVID-19
2. Emerging figures highlight the disparities in the mental health support provided to cancer patients. ... quality and accessibility of mental health support for cancer patients in the UK.
-
Growing evidence supports the important role of biosimilars in healthcare
Still, these patients are at a significant risk; based on a retrospective analysis of hospital discharge data, the inpatient case fatality rate associated with febrile neutropenia within breast cancer patients was ... the potential higher risk of
-
Unlocking the potential of precision medicine in oncology
It is for people like my father, the hundreds of cancer patients I treated as a physician, and indeed my family, that I am so dedicated to my work every single ... continuum of targeted therapies now available to prostate cancer patients, including PARP
-
What Hemingway got right about patient communications
about. Digital care for cancer patients. It’s not just a pharma phenomenon: there has also been a huge digital pivot in how our health charity clients now offer care services. ... Pre-COVID-19, breast cancer patients wanting to access resources like
The lessons learned from COVID-19’s impact on oncology trials
The impact of cancer on mental health during COVID-19
Growing evidence supports the important role of biosimilars in healthcare
Unlocking the potential of precision medicine in oncology
What Hemingway got right about patient communications
More from intelligence
Approximately 0 fully matching, plus 65 partially matching documents found.
Latest appointments
-
Genmab appoints Tahamtan Ahmadi as chief medical officer, head of experimental medicines
promise to create, develop and bring truly differentiated next-generation antibody medicines to cancer patients,” he added.
-
Merck’s R&D chief Roger Perlmutter heads for the exit as Dean Li takes the helm
newly-diagnosed non-small cell lung cancer (NSCLC) patients.
-
Ex-Roche CMO Sandra Horning joins Gilead’s board of directors
During her ten-year career at Roche, Horning helped to bring 15 new medicines to patients in a range of diseases, including cancer, multiple sclerosis, influenza and blindness. ... In addition, she brings the perspective of a leading physician who has
-
F-star hires ex-BMS immuno-oncology leader
pipeline. As we saw at the recent ASCO meeting, bispecific antibodies are leading a paradigm shift in cancer care and the potential to improve the outcome for cancer patients has never ... He is an active member of the American Society of Clinical
-
New hires at Ferring, Flexion and Immunocore
It’s the first major appointment for Ferring in 2019, and the company says Opdyke will lead the potential commercial launch of its investigational gene therapy for bladder cancer patients in ... He said: “At the heart of cancer immunity is a T cell
Genmab appoints Tahamtan Ahmadi as chief medical officer, head of experimental medicines
Merck’s R&D chief Roger Perlmutter heads for the exit as Dean Li takes the helm
Ex-Roche CMO Sandra Horning joins Gilead’s board of directors
New hires at Ferring, Flexion and Immunocore
More from appointments
Approximately 0 fully matching, plus 35 partially matching documents found.
Latest from PMHub
-
Building Better Patient Advocates Through Authentic Partnerships
Sabrina Hanna, Founder &CIO of the Cancer Collaborative, discusses precision medicine, innovation in oncology, how to build better patient advocates, and the current gaps when it comes to patient-centricity in
-
Clinical trial design and how it can be used to improve the patient experience
These trial designs only have one treatment option, with no placebo, and are usually in clinical fields such as cancer or stroke where patients experience acute illness and may not have ... In these circumstances, it can be considered unethical to offer
-
Clinical trial branding: 5 reasons it’s important to your clinical trials
In a 2005 survey of just under 2000 cancer patients, 73% of those who participated in a clinical trial say that they took part based on their HCP’s awareness of ... Especially considering that 43% of patients use the internet to find relevant
-
How innovating study sites can improve patient recruitment efficiency
Or, maybe you don’t know that you’re eligible, which was the case for 85% of surveyed newly-diagnosed cancer patients.. ... The use of tools and tech at sites is normally reserved for the point where patients enter randomisation.
-
Alternative Approaches to Personalized Medicine in Oncology
Laura Towart, Founder &CEO of My Personal Therapeutics, discusses her company’s approach to precision medicine, the barriers patients with cancer face when trying to access personalized treatments, and how the
Clinical trial design and how it can be used to improve the patient experience
Clinical trial branding: 5 reasons it’s important to your clinical trials
How innovating study sites can improve patient recruitment efficiency
More from PMHub
Approximately 2 fully matching, plus 69 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
-
CEO Pricing & Market Access, UK
-
Six figure salary
- Medical Writers (All levels) Editorial / Scientific Leads & ...
-
Highly Competitive Remuneration packages
- Embattled Biogen talks up Aduhelm
- First oral antiviral drug for COVID-19 reviewed by Health Canada
- David Hunt launches independent agency The Considered
- One dose of AZ’s COVID-19 vaccine ‘highly effective’ against severe disease from variants
- bluebird bio gears up for split
- EU identifies first five ‘promising’ COVID-19 drugs as part of therapeutics strategy
- Health For All
- Digitalizing Muskuloskeletal Care to Improve Patient Outcomes and Reduce Cost
- Accelerating Drug Development Timelines with Big Data Analytics
- A Lucid Group Thirsty Thursday Special: Beautiful Rejects
- EU “still interested” in Valneva COVID vaccine despite UK snub
- US orders 1.4 million more doses of Regeneron antibody cocktail
- Oxford PharmaGenesis wins Communiqué Medical Affairs Agency of the Year award at Communiqué 2021
- Merck’s anti-COVID drug molnupiravir moves to phase 3 for prevention
- EU “still interested” in Valneva COVID vaccine despite UK snub
- FDA’s director and deputy director of its Office of Vaccines Research & Review resign
- Lilly to target difficult-to-treat disease through tie-up with Lycia
- Sanofi/Regeneron bag first approval for Actemra rival sarilumab
Latest intelligence
- Health literacy in the time of COVID-19
- In a time when much of the media’s focus is on the ongoing COVID-19 pandemic and the differences in vaccination rates between various regions, countries, and socioeconomic groups, improving health...
- Rare thoughts & outcomes - navigating pathways to better outcomes in rare
- ...
- How to pick the perfect training program for your healthcare professionals
- You know your team needs training. But not all training providers and programs are created equal. Last week, we shared the benefits of working with specialist learning and development (L&D)...
